On March 11, 2026, the Medicines Evaluation Board (MEB) in the Netherlands published new declaration guidance for applicants seeking Duplex marketing authorisation for human medicinal products. The update introduces a formal declaration process outlining supplementary regulatory conditions that must be met for approval and ongoing compliance. It applies to all relevant applications from the date of publication.
Details of the Update
The new guidance requires applicants to submit a completed declaration form as part of any Duplex marketing authorisation application, which enables the parallel marketing of identical or closely related medicinal products.
The declaration specifies supplementary conditions that applicants must meet, including requirements related to product quality, safety monitoring, and ongoing compliance obligations. These conditions are designed to ensure that parallel-marketed medicines maintain alignment with Dutch regulatory standards throughout their lifecycle.
The requirement applies to all new applications for Duplex marketing authorisation for human use medicines in the Netherlands. While the guidance was published in 2026, the effective compliance requirement dates back to January 1, 2022, meaning that adherence is mandatory for continued market access.
Why It Matters
This update strengthens regulatory clarity by formalizing expectations for Duplex marketing authorisation applications. It supports consistent compliance standards across parallel-marketed medicines while reinforcing ongoing safety and quality oversight. By introducing a structured declaration process, the MEB also promotes operational efficiency and reduces ambiguity in submission requirements, minimizing the regulatory burden associated with incomplete or misaligned applications.
Who This Affects
This update is relevant for Regulatory Affairs, Quality Assurance, Patient Safety, Legal/Compliance, and Commercial teams within pharmaceutical companies involved in the development, submission, and commercialization of human medicinal products in the Netherlands.
Next Steps
Organizations should review the updated declaration template and supplementary conditions to ensure alignment with current and upcoming Duplex marketing authorisation applications. Internal submission workflows, documentation standards, and compliance checklists should be updated in coordination with cross-functional teams to reflect these requirements.
As regulatory requirements continue to evolve across markets, staying aligned with country-specific submission expectations is critical.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is Duplex marketing authorisation in the Netherlands?
It is an authorisation pathway that allows the parallel marketing of identical or closely related medicinal products under specific regulatory conditions.
What is the new requirement introduced by the MEB?
Applicants must now submit a completed declaration form outlining compliance with supplementary conditions as part of their application.
What do the supplementary conditions cover?
They address product quality, safety monitoring, and ongoing compliance obligations for parallel-marketed medicines.
How can RegASK support compliance with Duplex marketing authorisation requirements?
RegASK helps teams track evolving regulatory requirements, align submission documentation with local conditions, and streamline compliance workflows, ensuring timely and accurate market authorisation processes.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
